Scarica l'app Stockscreener
24.80
5.67%
1.365
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Liquidity Mapping Around (RCUS) Price Events - Stock Traders Daily
Arcus halts Gilead-partnered late-stage trial for lung cancer drug - MSN
Arcus Biosciences (RCUS) Insider Trading Activity 2026 - MarketBeat
RCUS Assumes Buy by Truist Securities -- Price Target Raised to $35 - GuruFocus
Arcus Biosciences Coverage Assumed by Truist Securities at Buy - Moomoo
Truist assumes Arcus Biosciences stock with buy on RCC potential By Investing.com - Investing.com Canada
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Trimmed Their Revenue Forecasts By 21% - Sahm
Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts - Yahoo Finance
Why (RCUS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Top Arcus Biosciences (RCUS) Competitors 2026 - MarketBeat
What's going on with Arcus Biosciences stock on Wednesday? - MSN
Arcus Biosciences CFO Robert Goeltz sells $198,965 in stock By Investing.com - Investing.com Canada
Arcus Biosciences CFO Robert Goeltz sells $198,965 in stock - Investing.com
Arcus (NYSE: RCUS) director gifts 5,050 shares in estate move - Stock Titan
Arcus Biosciences (RCUS) CFO logs 7,763-share Rule 10b5-1 sale - Stock Titan
Arcus Biosciences stock (US75626R1077): Form 144 filing signals insider RSU sales - AD HOC NEWS
TradingKey - TradingKey
Arcus Biosciences (RCUS) Form 144: Brokered notice for RSU sales via Merrill Lynch - Stock Titan
RCUS Maintained by Morgan Stanley -- Price Target Raised to $22 - GuruFocus
Earnings call transcript: Arcus Biosciences misses Q1 2026 forecasts, stock dips - Investing.com Nigeria
Earnings call transcript: Arcus Biosciences misses Q1 2026 forecasts, stock dips By Investing.com - Investing.com South Africa
Arcus Biosciences Q1 Loss Of US$128 Million Reinforces Bearish Profitability Concerns - Sahm
Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report - Yahoo Finance
Arcus Biosciences, Inc. (NYSE:RCUS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
RCUS Maintained by Goldman Sachs -- Price Target Raised to $34 - GuruFocus
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
MSN Money - MSN
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Eton Pharmaceuticals (ETON) surges 19.8%: Is this an indication of further gains? - MSN
RCUS (RCUS) Rule 144: Issuer sells 77,793 shares via option exercise - Stock Titan
Arcus Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:RCUS) 2026-05-06 - Seeking Alpha
Arcus Biosciences | 10-Q: Q1 2026 Earnings Report - Moomoo
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift - Yahoo Finance
Arcus outlines PEAK-1 full enrollment by year-end 2026 with cash runway into 2H 2028 - MSN
Arcus Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
8-K: Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Updatemoomoo - Moomoo
Arcus (RCUS) Q1 2026 Earnings Call Transcript - AOL.com
Earnings call transcript: Arcus Biosciences Q1 2026 results miss expectations By Investing.com - Investing.com Nigeria
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Arcus Biosciences Q1 2026 results miss expectations - Investing.com
Arcus Biosciences Q1 Loss Narrows, Revenue Falls - marketscreener.com
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):